siRNA Septicemia Treatment Patent

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. covering an siRNA therapeutic targeting the kininogen (KNG) gene for treating septicemia. The patent includes 8 claims for the nucleic acid composition, pharmaceutical formulation, and siRNA conjugate. This is a standard patent grant公告 with no regulatory compliance obligations.

View original document View source feed page

What changed

USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. for an siRNA composition inhibiting kininogen (KNG) gene expression for septicemia treatment and prevention. The patent covers the sense strand (nucleotide sequence with ≤3 differences from SEQ ID NO: 1) and antisense strand (nucleotide sequence with ≤3 differences from SEQ ID NO: 2), along with pharmaceutical compositions and siRNA conjugates.

This is a routine patent grant with no compliance deadlines or required actions for external parties. Pharmaceutical and biotechnology companies developing siRNA-based sepsis therapeutics should note this existing patent portfolio when designing research programs to avoid potential infringement. The filing date was May 21, 2020, with Application No. 17595621.

Source document (simplified)

← USPTO Patent Grants

Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Grant US12590304B2 Kind: B2 Mar 31, 2026

Assignee

SUZHOU RIBO LIFE SCIENCE CO., LTD.

Inventors

Hongyan Zhang, Shan Gao, Daiwu Kang

Abstract

An siRNA which inhibits kininogen (KNG) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I, nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotide differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotide differences. The siRNA, the pharmaceutical composition thereof and the siRNA conjugate can effectively treat and/or prevent septicemia.

CPC Classifications

C12N 15/113 C12N 2310/14 C12N 2310/315 C12N 2310/322 C12N 2310/351 C12N 2320/11 C12N 2330/30 C12N 2310/343 C12N 2310/346 C12N 2310/3517 C12N 2320/32 A61K 47/549 A61K 31/713 A61K 47/54 A61P 31/04 A61P 21/00 A61P 21/04 A61P 37/00 C07H 21/02